Biologics In Focus
Welcome to ‘Biologics In Focus’, the new newsletter from Lonza Biologics.
We are a fully integrated CDMO that offers end-to-end innovative development and manufacturing services across mammalian, bioconjugates, microbial and mRNA modalities, from late phase drug discovery to market supply. With a presence on three continents and working with small biotech to large pharmaceutical companies, we deliver expertise, efficiency and value across the molecule lifecycle.
Each month we will deliver deep analysis of industry trends, expert insights, and an overview of upcoming events - as well as the latest Lonza news and real world customer stories. Essential reading for all in the biologics sector.
Lonza News and Updates
In March, Lonza announced that it signed an agreement to acquire a large-scale biologics manufacturing site in Vacaville, California from Roche. The move will offer customers access to additional manufacturing capacity and ensure further support for next generation mammalian biologics therapies. The site has a total bioreactor capacity of around 330,000 liters, and Lonza plans to invest approximately CHF 500 million in additional CAPEX to upgrade the facility. Read the full news release here
Last month, Epsilogen and Lonza announced the successful GMP manufacturing of MOv18 IgE, an IgE antibody targeting ovarian cancer, for use in a Phase Ib study. This milestone underscores the potential of IgE antibodies as a novel class of cancer therapies. Find out more here
You can find more news from across Lonza on our website?
Insights and Analysis
Read Lonza’s survey which identifies key development hurdles for next-gen therapeutics. The report identifies the challenges in upstream, downstream and analytical development of new molecular formats, and provides insights into how processes could be refined to ensure the timely delivery of future treatments to patients.?Find the survey here
Lonza in the Press
Angela Armanni, Matthew Jones and Bhroma Patel spoke to Labiotech about the crucial role of tech transfers in biologics. In the article, they outline the process’s stages: knowledge transfer, preparation, execution, and close-out, emphasizing their importance for efficient drug development and delivery, and key factors for successful transfers. Read more
Customer Case Study
领英推荐
In this article, Asher Biotherapeutics discusses the tech transfer of its lead fusion protein candidates. It sought a CDMO that could support programs through later phases and into commercial production, while simultaneously working with candidates in earlier stages. Find out about the process and some of the key learnings. Read their story here
Upcoming Events
To meet with our team at BIO International, please contact us here
BioTalk Presentations
May 8, 09.30: Innovative analytical strategies for new molecular format CMC development for BLA
May 8, 15.20: Accelerating the Development of New Molecular Formats: Speed to Clinic
Find out more and book a meeting with our team here
Upcoming Webinars
Tuesday, April 30. 11am EDT | 5pm CET Register here
Innovative analytical strategies to address common development challenges of new molecular formats
Monday, May 6. 11am EDT | 5pm CET Register here
How to bring (any) mRNA to life - simplifying nucleic acid encapsulation
Tuesday, 28 May. 5pm EDT | Register here
Optimising the path to first-in-human clinical trials: an integrated approach to design and de-risk your candidate
Thank you for reading. Remember to subscribe so you never miss our monthly updates.